Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer

Abstract

Correspondence: Youguo Chen (youguo chen@163.com)Ovarian cancer (OC) is a malignant tumor with high mortality in women. Although cancer patients initially respond to paclitaxel chemotherapy following surgery, most patients will relapse after 12-24 months and gradually die from chemotherapy resistance. In OC, cancer cells become resistant to paclitaxel chemotherapy under hypoxic environment. The miR-27a has been identified as an oncogenic molecular in ovarian cancer, prostate cancer, liver cancer etc. In addition, the miR-27a is involved in hypoxia-induced chemoresistance in various cancers. However, the role of miR-27a in hypoxia-induced OC resistance remains unclear. The aim of the present study was to investigate the regulatory mechanism of miR-27a in hypoxia-induced OC resistance. The expression of HIF-1α induced Hypoxia overtly up-regulated. At the same time, hypoxia increased viability of Skov3 cells and decreased cell apoptosis when treated with paclitaxel. The expression of the miR-27a was obviously up-regulated under hypoxia and involved in hypoxia-induced paclitaxel resistance. Follow-up experiments portray that miR-27a improved paclitaxel resistance by restraining the expression of APAF1 in OC. Finally, we further elucidated the important regulatory role of the miR-27a-APAF1 axis in OC through in vivo experiments. According to our knowledge, we first reported the regulation of miR-27a in hypoxia-induced chemoresistance in OC, providing a possible target for chemoresistance treatment of OC.

Recent advances and future directions in anti‐tumor activity of cryptotanshinone: A mechanistic review

“…Several studies have confirmed that cancer cells are able to reduce their sensitivity into PTX chemotherapy using oncogene factors (Feng et al, 2020; Gu, Li, Liu, Lu, & Zhu, 2020). CT can be considered as a chemosensitizer.…”

Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy

“…During hypoxia, the level of HIF1 protein increases, and the HIF‐mediated pathway affects metabolic adaptation through mammalian target of rapamycin (mTOR) signaling, erythropoiesis, angiogenesis, cell growth, vascular tone, and differentiation. Hypoxia is generally considered as a factor that promotes the tumor development, such as hypoxia‐induced tumor chemotherapy resistance [ 81,82 ] and epithelial‐mesenchymal transformation. [ 83–85 ] Hypoxia is also a factor that must be considered in PDT, because oxygen is the third necessary factor in addition to photosensitizers and NIR light.…”

Participation of MicroRNAs in the Treatment of Cancer with Phytochemicals

“…Moreover, miR-27a-3p is increased by the hypoxic condition and advances resistance to paclitaxel by targeting apoptotic protease-activating Factor 1 (APAF1), a mediator of cytochrome c-dependent caspase activations, in ovarian cancer cells [ 297 ] ( Figure 5 and Table 6 ).…”